Genizon BioSciences Collaborating with NDEI to Enhance Gene Discovery Findings in Schizophrenia

08-Nov-2007

Genizon BioSciences Inc. and Neuropsychiatrie, Decouverte & Innovation Inc. (NDEI) announced an agreement under which the groups will collaborate to enhance and potentially add to discoveries made by Genizon early this year in a genome-wide association study of schizophrenia. Genizon's study identified multiple genes associated with the disease using DNA samples from patients from the Quebec Founder Population.

NDEI, under the leadership of Dr. Michel Maziade, president of NeuroCite, scientific director of the Centre de recherche Universite Laval Robert-Giffard (CRULRG) and professor of Psychiatry at the University of Laval, will be supplying a second set of samples collected from the Quebec Founder Population. Genotyping of these samples and statistical analyses of the data will be conducted at Genizon's St. Laurent, Quebec research center.

"We are delighted to be working with Dr. Maziade and his group," said Dr. John Hooper, President and CEO of Genizon. "They have advanced expertise in schizophrenia research, and this collaboration has significant potential to enhance our discoveries in this disease."

Genizon has conducted eight genome-wide association studies to date, covering a range of therapeutic areas. All studies have used samples from the Quebec Founder Population which, because of its high level of genetic homogeneity, is considered among the best populations worldwide for disease gene discovery.

Genizon and NDEI are dedicated to accelerating the development of diagnostic and therapeutic solutions to schizophrenia.

https://www.bionity.com/en/news/73928/genizon-biosciences-collaborating-with-ndei-to-enhance-gene-discovery-findings-in-schizophrenia.html